Komentář k doporučení Americké gastroenterologické asociace (AGA) pro léčbu středně těžké a těžké Crohnovy nemoci
Milan Lukáš1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. FeuersteinJD, HO EY, Shmidt E et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroentreology 2021; 160(7): 2496–2508. doi: 10.1053/j.gastro.2021.04.022.
2. Singh S, Proctor D, Scott FI et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroentreology 2021; 160(7): 2512–2556. doi: 10.1053/j.gastro.2021.04.023.
3. Ho EY, Singh S, Terdiman JP. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroentreology 2021; 160(7): 2557–2562. doi: 10.1053/j.gastro.2021.04.024.
4. Terdiman JP, Gruss CB, Heidelbaugh JJ et al. AGA Insitute Clinical Practice and Quality Management Committee. American Gastroentreogical Association Institure guidelines on the of thiopurines, methotrexate, and anti TNF biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 2013; 145(6): 1459–1463. doi: 10.1053/j.gastro.2013.10.047.
5. Torres J, Bonovas S, Doherty G et al. ECCO guidelines on therapeutics in Crohn’ s disease: medical treatment. J Crohn’s Colitis 2020; 14(1): 4–22. doi: 10.1093/ecco-jcc/jjz180.